ArticleEuropean journal of pediatrics2011
Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use.
Article in European journal of pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Pooled it
- Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.The Cochrane database of systematic reviews · 2016Pooled it
- A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.Journal of perinatology : official journal of the California Perinatal Association · 2012Trial
- Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Review
- Bosentan as adjunctive therapy in neonates with congenital diaphragmatic hernia-associated pulmonary hypertension: a case series.European journal of pediatrics · 2025Article
- Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.Cardiology in the young · 2025Article
- Giant omphalocele associated pulmonary hypertension: A retrospective study.Frontiers in pediatrics · 2022Article
- Management Practices During Perinatal Respiratory Transition of Very Premature Infants.Frontiers in pediatrics · 2022Review
- Review
- Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm.European journal of pediatrics · 2021Review
- Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups.American journal of physiology. Lung cellular and molecular physiology · 2016Article
- Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2016Review
- Assessing pulmonary arterial hypertension in infants with severe chronic lung disease of infancy: a role for a pulmonary artery catheter?Pediatric cardiology · 2013Article
- Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.Pediatric pulmonology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature infants with preterm premature rupture of membranes (PPROM) are at high risk of severe respiratory failure because of lung hypodysplasia associated with persistent pulmonary hypertension of the newborn (PPHN). We describe the clinical course of a 28-week gestation infant with PPROM from the 20th week and prolonged oligohydramnios before delivery, who developed refractory hypoxia treated with oral bosentan as adjunct therapy to inhaled nitric oxide (iNO) and oral sildenafil. Conclusion Our experience suggests that bosentan can be used in the premature infant with PPHN after PPROM. To the best of our knowledge, this is the first report of bosentan treatment in a premature infant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.